Schrödinger (NASDAQ:SDGR) Announces Earnings Results, Misses Estimates By $0.20 EPS

Schrödinger (NASDAQ:SDGR) posted its quarterly earnings data on Wednesday. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20), Zacks reports. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The business had revenue of $88.32 million during the quarter, compared to the consensus estimate of $83.20 million. Schrödinger updated its FY 2025 guidance to EPS.

Schrödinger Stock Down 0.5 %

SDGR stock traded down $0.11 during trading on Friday, hitting $22.14. The company had a trading volume of 463,465 shares, compared to its average volume of 1,011,639. The firm has a 50-day moving average price of $22.29 and a 200-day moving average price of $20.57. Schrödinger has a 12 month low of $16.67 and a 12 month high of $29.15. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -9.47 and a beta of 1.61.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on SDGR shares. KeyCorp increased their price target on shares of Schrödinger from $25.00 to $27.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Piper Sandler lowered their price target on Schrödinger from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday. Finally, BMO Capital Markets upped their target price on shares of Schrödinger from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $31.56.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.